New work describes the ability of Selective Organ Targeting (SORT) lipid nanoparticles (LNPs) to facilitate high levels of persistent gene editing in lung stem cells when given systemically via intravenous injection. This is the first study to show that LNPs carrying gene editing tools can effectively correct a gene in lung stem cells when administered intravenously and delivered through systemic circulation.